Washington Research Foundation

Viata offers hotel booking and comparative pricing for users.

Pacific Northwest Research Institute is a research institute for genetics and bioinformatics research.

Monod Bio is a life sciences company headquartered in Seattle, Washington, specializing in the development of innovative biosensors for the detection of proteins, toxins, antibodies, and other analytes. Founded in 2021, the company leverages advances in computational protein engineering to create modular bio-sensing nanoswitches. These biosensors integrate binding, transduction, and amplification processes in a single step, allowing for rapid, sensitive, and cost-effective analytical assays. Monod Bio's technology aims to enhance the capabilities of the healthcare industry by providing advanced tools for biotechnology and medical applications.

SEngine Precision Medicine, Inc. is a Seattle-based company that specializes in personalized cancer treatment solutions. Founded in 2015, it operates a unique platform that utilizes functional genomics and robotic testing to analyze live patient organoids. This innovative approach allows the simultaneous testing of over 200 cancer drugs against an individual's tumor, providing insights into the most effective and least toxic treatment options that traditional DNA sequencing may not uncover. The company’s proprietary P.A.R.I.S assay empowers patients and oncologists with tailored treatment options, enhancing the decision-making process in oncology. Additionally, SEngine aggregates anonymized testing results to aid in the development of new cancer-targeted drugs, positioning itself at the forefront of precision medicine in oncology.

Cyrus Biotechnology, Inc. is a Seattle-based company that specializes in developing advanced software for protein structure prediction and design. Founded in 2014, it offers several key products, including Rosetta, a tool designed to create biologically active proteins for various medical applications such as treating brain cancer and addressing Celiac Disease. The company also provides Cyrus Bench, an enterprise version of Rosetta that includes a comprehensive suite of bio-molecular computation tools. Additionally, Cyrus Biotechnology offers specialized services like Cyrus CryoEM, which focuses on structure refinement and model building for complex biomolecular structures. Its innovative software solutions cater to pharmaceutical companies, biotech firms, and startups engaged in discovering therapeutics and developing novel consumer products.

Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

AdaptX is a Seattle-based healthcare technology company established in 2016, spun out from Seattle Children's Hospital. It specializes in data analytics, visualization, and AI for hospitals and surgery centers. The company's core product is a clinical healthcare analytics platform that integrates with institutions' existing electronic data systems. This platform enables medical professionals to monitor, analyze, and improve clinical outcomes and workflows, ultimately enhancing care quality and reducing costs. AdaptX empowers both medical leaders and frontline clinicians to make data-driven decisions, transforming clinical operations within healthcare providers' facilities.

Medcurity, Inc. is a healthcare technology company based in Spokane, Washington, established in 2018. It specializes in developing a compliance management platform that assists healthcare systems in navigating HIPAA and security requirements. The platform offers an intuitive interface with tools and resources designed to build or enhance HIPAA privacy and security programs. Key features include a comprehensive survey that supports multiple users and devices, along with an online action item tracking dashboard that facilitates risk assessments. This enables healthcare professionals to effectively track the status of compliance efforts and understand their responsibilities through embedded guidance.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

AdaptX is a Seattle-based healthcare technology company established in 2016, spun out from Seattle Children's Hospital. It specializes in data analytics, visualization, and AI for hospitals and surgery centers. The company's core product is a clinical healthcare analytics platform that integrates with institutions' existing electronic data systems. This platform enables medical professionals to monitor, analyze, and improve clinical outcomes and workflows, ultimately enhancing care quality and reducing costs. AdaptX empowers both medical leaders and frontline clinicians to make data-driven decisions, transforming clinical operations within healthcare providers' facilities.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Phase Genomics is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in developing technology for ProxiMeta Hi-C genome assembly and metagenome deconvolution. Phase Genomics' platform aims to facilitate transformative discoveries in agriculture, human health, and industrial biology by providing scientists with highly accurate and detailed genomes and metagenomes. This enables researchers to make significant breakthroughs across various fields.

Phytelligence, Inc. is an agricultural biotechnology company that specializes in the cultivation and provision of disease-free plants and innovative solutions for growers, nurseries, and horticultural experts. Founded in 2012 and based in Pullman, Washington, the company offers a diverse range of tissue-cultured plantlets, including pear, apple, cherry, sweet cherry, grape, and strawberry. Phytelligence utilizes advanced propagation techniques and genetic analysis services to ensure the high quality and genetic integrity of its plants, enabling clients to achieve greater profitability through improved speed to harvest and reduced input costs. Its product portfolio also includes various series of rootstocks, such as the Geneva, Gisela, and Krymsk series, contributing to healthier and more resilient crops.

Rodeo Therapeutics Corp. is a Seattle-based drug development company that focuses on creating novel small molecule therapies aimed at tissue repair and regeneration. Founded in 2017, the company targets specific biological pathways and enzyme mechanisms critical for healing. Its primary objectives include developing treatments for inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Rodeo's innovative approach involves increasing tissue levels of prostaglandin PGE2 by inhibiting the enzyme 15-PGDH, which has shown promise in protecting against colitis and promoting liver regeneration in various animal models. This research positions Rodeo Therapeutics to contribute significantly to the medical management of these conditions.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

WiBotic Inc. is a company specializing in wireless charging and power optimization solutions for robotic systems, including aerial, mobile, and underwater vehicles. Established in 2014 and headquartered in Seattle, Washington, WiBotic develops a range of products, including wireless charging systems, transmitters, onboard chargers, and antenna coils, as well as professional services. The company also offers advanced power management software that enhances battery performance and optimizes the operational efficiency of entire fleets of robots. This technology automatically detects when a robot or drone approaches a charging platform, facilitating seamless and autonomous battery charging. WiBotic's solutions are designed to be safe, reliable, and scalable, enabling clients to reduce charging and maintenance costs while maximizing battery lifespan and operational capabilities.

HyperSciences Inc., established in 2014 with headquarters in Spokane, Washington and an additional office in Austin, Texas, specializes in high-velocity drilling solutions for diverse applications such as tunneling, energy, transportation, aerospace, and materials production. The company's core product, HyperDrill, significantly enhances drilling speed by up to 10 times compared to conventional methods, catering primarily to the oil and gas, geothermal, construction, mining, and tunneling industries. HyperSciences' innovative technology employs low-cost chemical energy to accelerate consumable projectiles to hypersonic velocities, facilitating faster and deeper rock breaking and pulverization across varied conditions.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.

Nexgenia Inc., established in 2011 and based in Seattle, Washington, specializes in the development and manufacturing of proprietary polymer-based reagents for therapeutic and diagnostic applications. The company's core products are stimuli-responsive polymers and polymer-containing magnetic nanoparticles, which can change their state in response to minor environmental changes like temperature, pH, or salt concentration. These smart materials enable faster, more efficient molecular separations and immunoassays, benefiting diagnostic and life science applications by facilitating quicker results for physicians.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

AnswerDash, Inc. is a technology company that specializes in providing contextual answer services for websites and mobile applications. Founded in 2012 and based in Seattle, Washington, AnswerDash offers a cloud-based platform that allows businesses to deliver self-service, point-and-click answers to users, thereby improving customer experience and reducing support costs. The platform integrates seamlessly with existing live chat services, enabling customers to seek personalized assistance when needed. By predicting user questions based on web page content and employing artificial intelligence, AnswerDash ensures that relevant information is readily available at the point of action. The company was previously known as Qazzow, Inc. until its name change in May 2014 and currently operates as a subsidiary of CloudEngage, Inc.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

C-SATS provides a personalized surgical skills assessment platform using a unique combination of data analytics, artificial intelligence. It specializes in the fields of robotic surgery, surgical skills, surgical insights, laparoscopic surgery, and minimally invasive surgery. The company was founded in 2014 and headquartered in Seattle, Washington.

Cardeas Pharma is focused on developing an innovative antibiotic formulation that combines two drugs to target highly resistant Gram-negative bacilli, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is designed to treat serious respiratory infections in critical care settings, particularly those caused by antibiotic-resistant organisms. Additionally, it demonstrates efficacy against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and has activity on biofilms. The delivery system utilizes a single-patient use, vibrating-plate nebulizer compatible with all ventilators, which generates small, uniform aerosol droplets that effectively reach the small airways and alveoli. By integrating this novel antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to achieve substantial clinical improvements over current treatment standards.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

FlexMinder, Inc. is a Seattle-based company that specializes in developing enterprise software solutions for private health exchanges, health carriers, and third-party administrators. Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, specifically for flexible spending accounts. The company's software aggregates healthcare information from various sources, streamlining the claims submission process for participants and significantly reducing manual processing time and costs for third-party administrators. By offering online tools that enhance the management of healthcare reimbursement accounts, FlexMinder aims to improve user experience and facilitate better financial management in the healthcare sector. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

Skytap, Inc. is a provider of cloud-based solutions focused on modernizing and migrating enterprise applications. Headquartered in Seattle, Washington, with additional locations in Toronto and London, Skytap offers the Skytap Cloud platform, which facilitates self-service access to production-like environments for development and testing teams, promoting more frequent code testing. The company integrates cloud automation with existing processes, allowing organizations to build, run, and evolve hybrid applications efficiently while adopting modern development practices such as agile and DevOps. Skytap's services encompass cloud migration, application modernization, and strategic consulting, all aimed at enhancing the speed, safety, and efficiency of application development to meet the demands of the digital services economy. Founded in 2006, Skytap was initially known as illumita, Inc. until its rebranding in 2008.

AnswerDash, Inc. is a technology company that specializes in providing contextual answer services for websites and mobile applications. Founded in 2012 and based in Seattle, Washington, AnswerDash offers a cloud-based platform that allows businesses to deliver self-service, point-and-click answers to users, thereby improving customer experience and reducing support costs. The platform integrates seamlessly with existing live chat services, enabling customers to seek personalized assistance when needed. By predicting user questions based on web page content and employing artificial intelligence, AnswerDash ensures that relevant information is readily available at the point of action. The company was previously known as Qazzow, Inc. until its name change in May 2014 and currently operates as a subsidiary of CloudEngage, Inc.

FlexMinder, Inc. is a Seattle-based company that specializes in developing enterprise software solutions for private health exchanges, health carriers, and third-party administrators. Founded in 2011, FlexMinder focuses on automating the healthcare reimbursement process, specifically for flexible spending accounts. The company's software aggregates healthcare information from various sources, streamlining the claims submission process for participants and significantly reducing manual processing time and costs for third-party administrators. By offering online tools that enhance the management of healthcare reimbursement accounts, FlexMinder aims to improve user experience and facilitate better financial management in the healthcare sector. As of January 2017, FlexMinder operates as a subsidiary of Jelleyvision Lab Inc.

Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing innovative biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product candidates, RSLV-132 and RSLV-133, which are designed to target and degrade immune complexes that contribute to disease pathology. RSLV-132 is a mono-specific nuclease Fc-fusion protein aimed at preventing interferon activation and mitigating kidney damage, while RSLV-133 combines two different nuclease activities into a single therapeutic molecule. Founded in 2010, Resolve Therapeutics is rooted in pioneering research from the University of Washington School of Medicine, with a commitment to improving the lives of patients suffering from these chronic conditions.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.

Mirador Biomedical is a company that focuses on the development and manufacturing of innovative physiological pressure measurement devices. It collaborates with a team of experienced entrepreneurs, medical device professionals, physicians, and scientists to create cost-effective solutions that enhance medical procedures. Their product offerings include devices for compass vascular access, lumbar puncture, compartment pressure measurement, thoracentesis, and vascular access lock systems. By providing physiological feedback, Mirador Biomedical aims to reduce doubt and uncertainty in common medical practices, ultimately improving patient outcomes and procedural efficiency.

Nimbic, headquartered in Mountain View, California, is a provider of cloud-based electronic design automation (EDA) solutions focused on electromagnetic integrity. The company offers advanced software that addresses signal integrity, power integrity, and electromagnetic interference challenges for the microelectronics industry, serving a diverse range of clients, including leading technology firms such as Texas Instruments, Renesas, and Panasonic. Nimbic's nCloud solution supports efficient chip-package-system co-design processes, significantly reducing both time-to-market and costs. With capabilities in 3D electromagnetic analysis, Nimbic’s technology showcases exceptional speed and capacity, enabling comprehensive simulations throughout the design cycle for microprocessors, FPGAs, and other complex systems while delivering accurate results without compromise.

Mirador Biomedical is a company that focuses on the development and manufacturing of innovative physiological pressure measurement devices. It collaborates with a team of experienced entrepreneurs, medical device professionals, physicians, and scientists to create cost-effective solutions that enhance medical procedures. Their product offerings include devices for compass vascular access, lumbar puncture, compartment pressure measurement, thoracentesis, and vascular access lock systems. By providing physiological feedback, Mirador Biomedical aims to reduce doubt and uncertainty in common medical practices, ultimately improving patient outcomes and procedural efficiency.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Skytap, Inc. is a provider of cloud-based solutions focused on modernizing and migrating enterprise applications. Headquartered in Seattle, Washington, with additional locations in Toronto and London, Skytap offers the Skytap Cloud platform, which facilitates self-service access to production-like environments for development and testing teams, promoting more frequent code testing. The company integrates cloud automation with existing processes, allowing organizations to build, run, and evolve hybrid applications efficiently while adopting modern development practices such as agile and DevOps. Skytap's services encompass cloud migration, application modernization, and strategic consulting, all aimed at enhancing the speed, safety, and efficiency of application development to meet the demands of the digital services economy. Founded in 2006, Skytap was initially known as illumita, Inc. until its rebranding in 2008.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

Corensic is a technology company that specializes in software quality tools designed to enhance the reliability of applications in multi-core environments. Founded in late 2008 and originally known as PetraVM, Corensic aims to support developers and IT organizations in building higher quality software. Its flagship product, Jinx, is a tool that helps identify and address concurrency bugs by increasing the likelihood of their occurrence during debugging, thereby allowing for more effective troubleshooting. Corensic's offerings include a Visual Studio extension and a command-line utility, which assist developers and testers in improving the performance and stability of both Windows and Linux applications.

Nimbic, headquartered in Mountain View, California, is a provider of cloud-based electronic design automation (EDA) solutions focused on electromagnetic integrity. The company offers advanced software that addresses signal integrity, power integrity, and electromagnetic interference challenges for the microelectronics industry, serving a diverse range of clients, including leading technology firms such as Texas Instruments, Renesas, and Panasonic. Nimbic's nCloud solution supports efficient chip-package-system co-design processes, significantly reducing both time-to-market and costs. With capabilities in 3D electromagnetic analysis, Nimbic’s technology showcases exceptional speed and capacity, enabling comprehensive simulations throughout the design cycle for microprocessors, FPGAs, and other complex systems while delivering accurate results without compromise.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, specializing in the development of therapeutic products for cancer and infectious diseases utilizing its proprietary Tarmogen platform. Founded in 1995 as Ceres Pharmaceuticals, the company focuses on creating targeted molecular immunotherapies. Its product pipeline includes GS-4774, currently in Phase 2 trials for chronic hepatitis B infection, and GI-6301, aimed at cancers expressing the brachyury protein. Additionally, GlobeImmune is advancing GI-6207 for medullary thyroid cancer and GI-4000 for resected pancreatic cancer, with multiple Phase 2 clinical trials for various other cancers, including non-small cell lung cancer and colorectal cancer. The company is also developing several candidates targeting infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D, which are in preclinical stages. GlobeImmune has established strategic collaborations with notable organizations, enhancing its research and development efforts.

Hyperion Therapeutics, Inc. is a biopharmaceutical company based in Brisbane, California, focused on developing and commercializing therapies for orphan diseases. The company specializes in treatments for urea cycle disorders (UCD), offering products such as RAVICTI, a nitrogen-binding agent used for the chronic management of UCD in both adults and pediatric patients. In addition to RAVICTI, Hyperion provides BUPHENYL and AMMONAPS for the treatment of specific UCD subtypes. The company is also exploring the application of glycerol phenylbutyrate, the active ingredient in RAVICTI, for the treatment of hepatic encephalopathy. Founded in 2006, Hyperion Therapeutics aims to address the needs of underserved patient populations through its innovative therapeutic developments.

Accelerator Corporation, founded in 2003 and based in Seattle, Washington, is a venture capital firm that specializes in early-stage investments in biotechnology companies. The firm primarily invests up to $2 million in emerging growth and start-up ventures, focusing on identifying, evaluating, financing, and managing groundbreaking life sciences opportunities. Accelerator does not participate in subsequent financing rounds and typically maintains its investments for 12 to 24 months. The firm has developed a robust pipeline of deal flow through partnerships with top-tier investors and research institutions, providing access to state-of-the-art facilities and expertise in scientific and technical support. Over the past five years, Accelerator has invested in nine companies, three of which successfully raised follow-on financing exceeding $114 million. In total, Accelerator's portfolio companies have garnered over $143.5 million in initial and follow-on funding, supported by an additional commitment of $22.5 million from investors to further pursue innovative biotechnology opportunities. Through its unique resources and collaborations, Accelerator is positioned to streamline the development and commercialization of novel technologies in the biotechnology sector.

Skytap, Inc. is a provider of cloud-based solutions focused on modernizing and migrating enterprise applications. Headquartered in Seattle, Washington, with additional locations in Toronto and London, Skytap offers the Skytap Cloud platform, which facilitates self-service access to production-like environments for development and testing teams, promoting more frequent code testing. The company integrates cloud automation with existing processes, allowing organizations to build, run, and evolve hybrid applications efficiently while adopting modern development practices such as agile and DevOps. Skytap's services encompass cloud migration, application modernization, and strategic consulting, all aimed at enhancing the speed, safety, and efficiency of application development to meet the demands of the digital services economy. Founded in 2006, Skytap was initially known as illumita, Inc. until its rebranding in 2008.

HaloSource Corporation is a clean water technology company that focuses on developing and manufacturing innovative drinking water treatment solutions for global markets. Established in 2017 and headquartered in Bothell, Washington, the company leverages proprietary polymer chemistries to create a range of products aimed at improving water quality. Its offerings include gravity-based devices like the HaloPure disinfecting pitchers and associated cartridges, as well as pressurized devices such as bacteriostatic water cartridges and ceramic candle inserts. The HaloPure technology is recognized for its high international certifications, including registration with the US EPA, and serves over 10 million consumers worldwide. Additionally, HaloSource is expanding its product line to include lead removal media and is actively engaged in partnerships with trusted brands to further enhance its market presence. The company is well-positioned to capitalize on opportunities in the residential water treatment sector, supported by a robust pipeline of new products and strong regulatory compliance.

Omeros Corporation is a Seattle-based biopharmaceutical company that focuses on discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company offers OMIDRIA, a product used during cataract surgery in the United States. Omeros is advancing several clinical programs, including narsoplimab, which is in Phase III trials for conditions such as hematopoietic stem-cell transplant-associated thrombotic microangiopathy and immunoglobulin A nephropathy, as well as Phase II trials for lupus nephritis. Other key programs include OMS405, targeting opioid and nicotine addiction, and OMS527, aimed at treating addiction and movement disorders. The company's preclinical pipeline includes compounds addressing various conditions, such as paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Founded in 1994, Omeros is dedicated to addressing both large-market and orphan indications through innovative therapeutic approaches.

Targeted Growth, Inc. is a crop biotechnology company based in Seattle, Washington, with additional laboratories in the United States and Canada. Founded in 1998, the company specializes in developing technologies that enhance seed size and agricultural yields for both food and biofuel markets. Targeted Growth focuses on improving various crops, including canola, soybean, corn, and camelina, which are essential raw materials for renewable fuel production, such as ethanol and biodiesel. By increasing crop fertility and yield, Targeted Growth aims to support farmers and contribute to sustainable energy solutions.

Farecast is a fare-prediction service founded in 2003 that helps travelers determine the optimal time to purchase airline tickets. By analyzing 175 billion points of historical airfare data, Farecast predicts whether ticket prices will rise or fall up to a week in advance, boasting a success rate of 70-75%. This innovative approach distinguishes Farecast from other travel companies, as it is the only platform that offers such predictive capabilities. In addition to airfare predictions, Farecast has expanded its services to include hotel price comparisons, displaying results from various travel search sites on an interactive map. This feature helps users identify whether a hotel is overpriced or attractively priced, using color coding to highlight deals. Overall, Farecast aims to assist travelers in making informed decisions to save on travel costs.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.

Targeted Growth, Inc. is a crop biotechnology company based in Seattle, Washington, with additional laboratories in the United States and Canada. Founded in 1998, the company specializes in developing technologies that enhance seed size and agricultural yields for both food and biofuel markets. Targeted Growth focuses on improving various crops, including canola, soybean, corn, and camelina, which are essential raw materials for renewable fuel production, such as ethanol and biodiesel. By increasing crop fertility and yield, Targeted Growth aims to support farmers and contribute to sustainable energy solutions.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Teranode is a developer of software solutions aimed at enhancing decision-making in research and development within the life sciences sector. The company's platform focuses on real-time business intelligence, facilitating collaboration and laboratory automation. Teranode's technology enables executives and researchers to automate experiment workflows, manage biological data, and integrate information into customizable user views. By analyzing both structured and unstructured data from various sources, the platform provides contextual insights that help organizations in the healthcare and life sciences industries monitor compliance and regulatory standards. This innovative approach aims to transform the role of computing in scientific research, ultimately improving product life cycles and operational efficiency.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Farecast is a fare-prediction service founded in 2003 that helps travelers determine the optimal time to purchase airline tickets. By analyzing 175 billion points of historical airfare data, Farecast predicts whether ticket prices will rise or fall up to a week in advance, boasting a success rate of 70-75%. This innovative approach distinguishes Farecast from other travel companies, as it is the only platform that offers such predictive capabilities. In addition to airfare predictions, Farecast has expanded its services to include hotel price comparisons, displaying results from various travel search sites on an interactive map. This feature helps users identify whether a hotel is overpriced or attractively priced, using color coding to highlight deals. Overall, Farecast aims to assist travelers in making informed decisions to save on travel costs.

In the spring of 2002, Vanson, Inc. and HaloSource Corp. merged to form Vanson HaloSource, Inc. in order to expand opportunities for product commercialization by capitalizing on manufacturing facilities, distribution channels and intellectual property. Vanson’s cGMP certified manufacturing facility, located in Western Washington accommodates the production of most of Vanson HaloSource's products. The management team and a talented pool of chemists, biochemists and microbiologists are working together to create and expand the Company’s broad spectrum of applications. Today the Company holds dozens of patents and patents pending on a broad range of products that are distributed to the pool and spa, wastewater treatment, and biomedical industries. The Company has a substantial pipeline of proprietary new products in research and development, and a growing number of strategic alliances with prestigious companies to manufacture and market value-added chitin/chitosan-based and antimicrobial products.

Farecast is a fare-prediction service founded in 2003 that helps travelers determine the optimal time to purchase airline tickets. By analyzing 175 billion points of historical airfare data, Farecast predicts whether ticket prices will rise or fall up to a week in advance, boasting a success rate of 70-75%. This innovative approach distinguishes Farecast from other travel companies, as it is the only platform that offers such predictive capabilities. In addition to airfare predictions, Farecast has expanded its services to include hotel price comparisons, displaying results from various travel search sites on an interactive map. This feature helps users identify whether a hotel is overpriced or attractively priced, using color coding to highlight deals. Overall, Farecast aims to assist travelers in making informed decisions to save on travel costs.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Noting the growing trends in group travel, [Expedia](http://www.crunchbase.com/organization/expedia) and [Microsoft](http://www.crunchbase.com/organization/microsoft) vets founded TripHub in 2005. Based on the philosophy that "planning should be as fun as the trip," TripHub provides users with many different ways to facilitate group travel. Recently, Triphub [teamed up](http://about.triphub.com/2006/01/plan-talk-among.html) with [Orbitz](http://www.orbitz.com) to provide a ["powered by Triphub"](http://about.triphub.com/partners/index.html)group travel option. They are funded by Madrona Venture Group and other private investors. ###TripHub entered the deadpool on August 25, 2008.###